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ABSTRACT
Severe refractory asthma poses a substantial burden in
terms of healthcare costs but relatively little is known
about the factors which drive these costs. This study
uses data from the British Thoracic Society Difﬁcult
Asthma Registry (n=596) to estimate direct healthcare
treatment costs from an National Health Service
perspective and examines factors that explain variations
in costs. Annual mean treatment costs among severe
refractory asthma patients were £2912 (SD £2212) to
£4217 (SD £2449). Signiﬁcant predictors of costs were
FEV1% predicted, location of care, maintenance oral
corticosteroid treatment and body mass index. Treating
individuals with severe refractory asthma presents a
substantial cost to the health service.
INTRODUCTION
The global prevalence of asthma is estimated to be
300 million1 and approximately 18% of the UK
population have doctor diagnosed asthma.2 There
is a signiﬁcant economic burden associated with the
disease3 and an association between disease severity
and economic burden.4
A key issue in prior analyses is the deﬁnition of
severe asthma. This paper focuses on patients pre-
cisely characterised using systematic evaluation pro-
tocols as having severe refractory asthma (SRA) and
explores the direct annual treatment costs and
drivers of cost within this population from the per-
spective of a publicly funded provider.
METHODS
The data analysed are patient-speciﬁc anonymised
healthcare data drawn from the British Thoracic
Society National Registry for dedicated UK Difﬁcult
Asthma Services in 2012. Currently, seven UK
Specialist Difﬁcult Asthma Services submit data to the
Registry: Belfast City Hospital; Royal Brompton
Hospital, London; Glenﬁeld Hospital, Leicester;
University Hospital of South Manchester;
Birmingham Heartlands Hospital; Gartnavel
Hospital, Glasgow; and Stobhill Hospital, Glasgow.
After systematic multi-disciplinary assessment,
patients were classiﬁed using the American Thoracic
Society5 deﬁnition for refractory asthma (n=516)
and compared with a group with difﬁcult to manage,
but non-SRA disease (n=80).
Data from the Registry capture healthcare util-
isation including hospital admissions and general
practitioner/Accident & Emergency (GP/A&E)
unscheduled visits in the 12 months prior to being
ﬁrst seen at the difﬁcult asthma clinics. Published
references were used to monetise healthcare util-
isation and each aspect of care was multiplied by
this cost and aggregated to provide a total health-
care cost for the individual. As costs are estimated
for a 12-month time period, no discounting is
required.
All asthma-related medications were recorded at
the patient’s ﬁrst visit to the Difﬁcult Asthma
Service. Unit costs for medication were obtained
from the Prescription Cost Analyses for Northern
Ireland 2011.
Where data were not captured in the Registry,
estimates were made based on expert opinion,
using high/low cost scenarios. Scheduled GP visits
were estimated at one visit per year in the low cost
scenario and in the high cost scenario were
matched to unscheduled visits, where it was
assumed that each unscheduled GP/A&E visit
would be followed up with a scheduled GP visit.
Outpatient respiratory reviews were estimated at
two visits per year and include the cost of consult-
ant/nurse time and lung function tests. Additional
detail on the low/high cost scenario is presented in
the online supplementary material.
In addition to asthma treatments, the Registry
records any other medication received by the
patients. These were costed using a similar meth-
odology and are listed as non-asthma medication.
Asthma and non-asthma medication were identi-
ﬁed and categorised before analyses. Full refer-
ences are available in the online supplementary
material.
DATA ANALYSIS
After calculating total costs for each patient, a
series of regression analyses were used to examine
factors that explain variations in treatment costs
among SRA patients. Variables used to explain costs
(chosen based on available data) were gender, age,
clinical centre, best achieved FEV1, use of mainten-
ance oral corticosteroids (OCS), body mass index
(BMI) and smoking status. Analysis was carried out
using Stata 10.
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RESULTS
Figure 1 displays costs for healthcare utilisation and
asthma-related medication for SRA patients (see online supple-
mentary ﬁgure S1 for non-SRA costs), a breakdown of costs (see
online supplementary table A1), summary of demographic data
(see online supplementary table A2), medication costs in the
low/high cost scenarios (see online supplementary ﬁgures S2A
(SRA patients) and S2B (non-SRA patients)) and a breakdown of
medication, healthcare utilisation and associated costs (see
online supplementary tables A3–A7) together with comparisons
by hospital and of patient characteristics.
SRA patients had more unscheduled visits (SRA, median 4 (IQR
2–6) vs non-SRA, median 3 (IQR 0–6)) and hospital admissions
(SRA, median 0 (IQR 0–1), 274 of 516 (48%) had no admissions
vs non-SRA, median 0 (IQR 0–1), 43 of 80 (54%)), conﬁrming
that the admission rate in SRA patients in these specialist centres
was relatively low at referral (see online supplementary table A2).
The combined average cost of these medical services in the low
(high) cost scenario was £1207 (£2077) for SRA patients and
£935 (£1764) for non-SRA patients.
The major driver of cost was medication (see online supple-
mentary ﬁgure S2). Long acting bronchodilator/corticosteroid
combination inhalers represent the greatest share of medication-
related costs (£885–£1239 for SRA patients (low/high cost scen-
ario) and £425–£678 for non-SRA patients). Small numbers of
patients on oxygen (ﬁve SRA) and omalizumab (11 SRA)
incurred substantial costs (oxygen, individual patient cost £8908
and omalizumab, costing between £3330 and £26 640 depend-
ing on omalizumab dose) and cost differences were also noted
between clinical centres (see online supplementary table A7).
Regression analysis (online supplementary tables A8–A11, low
cost scenario) revealed that, after adjustment for covariates,
patients on maintenance OCS on average cost 43% more than
those not on maintenance steroids (95% CI 27% to 59%). Of
note also is that non-medication costs (19% greater (95% CI −4%
to 42%)) and non-asthma-related medication were also higher
(58% greater (95% CI 11% to 104%)) for these patients. Similar
results were evident in the high cost scenario (see online supple-
mentary tables A8–11). Patients requiring two or more rescue
courses of steroids had 31% higher costs (95% CI 14% to 48%)
illustrating the importance of recurrent exacerbations. For each
unit increase in percentage of predicted FEV1, there was an asso-
ciated 0.34% reduction in asthma-related medication costs (95%
CI −0.55% to −0.12%). In the high cost scenario, total costs for
severely obese SRA patients (BMI>40 kg/m2) are 17% higher than
those of normal weight patients (95% CI 0.3% to 34%).
DISCUSSION
This study examines the annual healthcare costs in a well-
characterised cohort of SRA patients and examines the distribu-
tion and drivers of costs in this population. A recent European
study demonstrated mean per patient costs in controlled asthma
of €509 (£451) and uncontrolled asthma €2281 (£2022),
similar to our non-SRA cost. Patients with SRA cost more com-
pared with other conditions (mean costs—type II diabetes
£2567; stroke £1301; COPD £819; chronic kidney disease
£235 (2% on renal replacement therapy £27 000)) (see online
supplementary materials for full discussion and references).
A key ﬁnding of the study is that asthma medication is the major
driver of total costs, not unscheduled GP/A&E or hospital admis-
sions. This implies that the overall cost of care in this population
will signiﬁcantly decrease if the price of multiple drug therapies
used by them falls. This is likely to be most apparent for inhaled
combination therapies, speciﬁcally with the arrival of generic com-
bination inhalers. Finally, future studies examining the effect of
novel therapies or interventions in SRA should consider a ‘medica-
tion reduction’ strategy in their development programme; speciﬁc-
ally, if a new therapy could provide a reduction in healthcare
utilisation in parallel with a reduction in maintenance asthma
medication use, it is more likely to be cost-effective.
We found that subjects on maintenance OCS are 43% more
expensive than those not receiving maintenance OCS. In those
on maintenance steroids, asthma-related medications were more
expensive but notably, their non-medication costs and
non-asthma-related medication were signiﬁcantly higher. Of
note, non-asthma medication includes proton pump inhibitor
and bisphosphonates, examples of therapies used to manage side
effects of OCS induced morbidity. Recurrent exacerbation is also
a signiﬁcant driver of costs; subjects with more than two exacer-
bations requiring OCS were approximately 31% more expensive
than subjects with less than two courses of rescue OCS.
Establishing the costs and cost drivers for SRA will aid policy-
makers examining the cost-effectiveness of currently available
‘add-on’ treatments such as omalizumab in this group. Recent
National Institute of Health and Care Excellence guidance on
omalizumab allows access to subjects receiving recurrent rescue
and maintenance OCS (see online supplementary materials for
reference). Our data support this analysis, as both subjects
requiring recurrent rescue OCS for exacerbation and mainten-
ance OCS appear more expensive based on our results.
However, it remains to be seen what additional costs are asso-
ciated with longer term maintenance OCS in this population.
The association between severe obesity (BMI >40) and asthma
cost is interesting—we have previously published data from the
Registry that indicate patients with SRA and obesity display par-
ticular characteristics and may represent a distinct clinical pheno-
type. Cluster analyses of severe asthma populations have also
identiﬁed obesity as an identiﬁable phenotype in severe asthma
(see online supplementary materials for full discussion and refer-
ences). The association with increased cost may reﬂect this altered
phenotype and poor response to treatment.
Our analysis does have some limitations. Non-National
Health Service and indirect costs were excluded, as were
Figure 1 Healthcare and asthma-related medication costs for severe
refractory asthma.
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dispensing fees, and so our cost estimates are likely to be conser-
vative. Similarly, as the Registry did not have complete records
for all healthcare visits, assumptions around these were
required; however, we do not think these threaten the validity
of our analyses, as scheduled and unscheduled healthcare visits
represent a minor element of total cost.
In conclusion, this paper has estimated treatment costs for
SRA patients in the UK to be £2912–£4217 per person per
year. These costs are greater than those for patients with poorly
controlled ‘difﬁcult asthma’ referred to the same clinics. The
costs are dominated by asthma medication costs and, import-
antly, these costs outweigh healthcare utilisation costs.
Maintenance OCS and frequent exacerbations are important
additional drivers of costs in this population.
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